Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens.

Martín-Castillo A, Castells MT, Adánez G, Polo MT, Pérez BG, Ayala I.

Biomed Pharmacother. 2010 Apr;64(4):275-81. doi: 10.1016/j.biopha.2009.06.003. Epub 2009 Oct 22.

PMID:
19932590
2.

Hyperlipidemic chicken as a model of non-alcoholic steatohepatitis.

Ayala I, Castillo AM, Adánez G, Fernández-Rufete A, Pérez BG, Castells MT.

Exp Biol Med (Maywood). 2009 Jan;234(1):10-6. doi: 10.3181/0807-RM-219. Epub 2008 Nov 7.

PMID:
18997102
3.

Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment.

Vilà L, Rebollo A, Ađalsteisson GS, Alegret M, Merlos M, Roglans N, Laguna JC.

Toxicol Appl Pharmacol. 2011 Feb 15;251(1):32-40. doi: 10.1016/j.taap.2010.11.011. Epub 2010 Nov 29.

PMID:
21122807
4.

Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.

Samy W, Hassanian MA.

Arab J Gastroenterol. 2011 Jun;12(2):80-5. doi: 10.1016/j.ajg.2011.04.008. Epub 2011 May 18.

PMID:
21684478
5.

Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats.

Ji G, Zhao X, Leng L, Liu P, Jiang Z.

Lipids Health Dis. 2011 Jan 26;10:23. doi: 10.1186/1476-511X-10-23.

6.

Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.

Ajamieh H, Farrell G, Wong HJ, Yu J, Chu E, Chen J, Teoh N.

J Gastroenterol Hepatol. 2012 Aug;27(8):1353-61. doi: 10.1111/j.1440-1746.2012.07123.x.

PMID:
22432744
7.

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H.

Cochrane Database Syst Rev. 2013 Dec 27;(12):CD008623. doi: 10.1002/14651858.CD008623.pub2. Review.

PMID:
24374462
8.

Intracellular retention of hepatic serpins caused by severe hyperlipidemia.

Hernández-Espinosa D, Ayala I, Castells MT, García-Pérez B, Martín-Castillo A, Miñano A, Arcas I, Vicente V, Corral J.

Liver Int. 2006 Aug;26(6):708-15.

PMID:
16842328
9.

Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.

Atalar E, Ozmen F, Haznedaroglu I, Açil T, Ozer N, Ovünç K, Aksöyek S, Kes S.

Int J Cardiol. 2002 Aug;84(2-3):227-31.

PMID:
12127376
10.

A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients.

Gómez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R.

Aliment Pharmacol Ther. 2006 Jun 1;23(11):1643-7.

11.

Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats.

Roglans N, Sanguino E, Peris C, Alegret M, Vázquez M, Adzet T, Díaz C, Hernández G, Laguna JC, Sánchez RM.

J Pharmacol Exp Ther. 2002 Jul;302(1):232-9.

12.

Physicochemical modifications induced by statins therapy on human erythrocytes membranes.

Broncel M, Bała A, Koter-Michalak M, Duchnowicz P, Wojsznis W, Chojnowska-Jezierska J.

Wiad Lek. 2007;60(7-8):321-8.

PMID:
18175550
13.

Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.

Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2589-600.

14.

Effects of atorvastatin on lipid metabolism in normolipidemic and hereditary hyperlipidemic, non-laying hens.

Elkin RG, Zhong Y, Donkin SS, Hengstschläger-Ottnad E, Schneider WJ.

Comp Biochem Physiol B Biochem Mol Biol. 2006 Mar;143(3):319-29. Epub 2006 Jan 18.

PMID:
16413806
15.

Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor.

Funatsu T, Kakuta H, Takasu T, Miyata K.

Eur J Pharmacol. 2002 Nov 29;455(2-3):161-7.

PMID:
12445582
16.

Non-alcoholic steatohepatitis in children.

Nanda K.

Pediatr Transplant. 2004 Dec;8(6):613-8. Review.

PMID:
15598336
17.

HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.

Bustos C, Hernández-Presa MA, Ortego M, Tuñón J, Ortega L, Pérez F, Díaz C, Hernández G, Egido J.

J Am Coll Cardiol. 1998 Dec;32(7):2057-64.

18.

Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties.

Uyuklu M, Meiselman HJ, Baskurt OK.

Clin Hemorheol Microcirc. 2007;36(1):25-33.

PMID:
17211059
19.
20.

Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.

Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ.

Arterioscler Thromb Vasc Biol. 2000 Jan;20(1):189-97.

Supplemental Content

Support Center